7 completed, 2 terminated, 2 unknown, 1 active not recruiting. 13 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 7, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Prevention: new trials by email Literature Review of Prevention trials Research Report on Prevention
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes Diamyd - Diabetes Mellitus, Type 1, Autoimmune Diseases | Phase 2 | Active not recruiting | Diamyd Medical AB | 5 | 2024-07-09 | 2026-04-20 |
| Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 FTC/TDF 200mg/300mg, FTC/TDF 300mg/450mg, FTC/TDF 400mg/600mg - HIV, Prevention | Phase 2 | Completed | University of North Carolina, Chapel Hill | 54 | 2024-06-18 | 2026-02-17 |
| PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients Pirfenidone/Placebo - Acute Lung Injury, Prevention | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 214 | 2023-03-16 | 2026-10-29 |
| A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years SCT1000, Gardasil®9, Gardasil® - Interventional, Prevention | Phase 2 | Unknown | Sinocelltech Ltd. | 1800 | 2021-10-19 | 2021-10-28 |
| Abatacept s.c. for aGVHD Prevention in Haplo-HCT Abatacept s.c. - Abatacept, Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 29 | 2021-06-01 | 2026-06-11 |
| Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) Rivaroxaban 2.5 Mg Oral Tablet, Rivaroxaban placebo tablets - Stroke, Prevention | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 42 | 2020-08-22 | 2023-10-19 |
| Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia Aztreonam lysine, Aerogen Solo, CombiHaler - Ventilator Associated Pneumonia, Prevention | Phase 2 / Phase 3 | Terminated | Hospital Universitari Joan XXIII de Tarragona. | 9 | 2019-03-19 | 2021-07-01 |
| Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring TFV/LNG IVR, TFV IVR, Placebo IVR - HIV, Contraception | Phase 2 | Unknown | CONRAD | 50 | 2018-12-12 | 2020-01-14 |
| Familias Unidas: Preventing Substance Abuse in Hispanic Youth Familias Unidas - Prevention, Family Function | Phase 2 / Phase 3 | Completed | University of Miami | 746 | 2010-08-01 | 2015-06-03 |
| Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine pandemic influenza vaccine (H5N1 strain NIBRG-14) - Pandemic Influenza, Prevention | Phase 2 | Completed | Sinovac Biotech Co., Ltd | 402 | 2007-09-01 | 2007-11-09 |
| Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. Azathioprine, Azathioprine in case of endoscopic recurrence, Ileocolonoscopy - Crohn Disease, Recurrence | Phase 2 | Terminated | Universitaire Ziekenhuizen KU Leuven | 63 | 2005-10-01 | 2015-05-29 |
| Parent Education for Young Teen Females parent education - Prevention | Phase 2 / Phase 3 | Completed | Education Development Center, Inc. | 500 | 2003-09-01 | 2012-07-03 |
| ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Rivaroxaban (BAY59-7939), Enoxaparin - Thromboembolism, Prevention | Phase 2 | Completed | Bayer | 641 | 2002-12-01 | 2014-12-17 |
Acute Lung Injury (1) · Autoimmune Diseases (1) · Breast Neoplasms (1) · Crohn Disease (1) · Diabetes Mellitus, Type 1 (1) · Immune System Diseases (1) · Metabolic Diseases (1) · Pneumonia, Ventilator-Associated (1) · Recurrence (1) · Sexual Behavior (1) · Smoking (1) · Stroke (1) · Substance-Related Disorders (1) · Thromboembolism (1)
Cardiovascular Diseases (2) · Disease Attributes (2) · Lung Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Vascular Diseases (2) · Behavior (1) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Chemically-Induced Disorders (1) · Cross Infection (1) · Diabetes Mellitus (1)
Rivaroxaban (2) · Azathioprine (1) · Enoxaparin (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Tenofovir (1) · pirfenidone (1)
Bayer (1) · CONRAD (1) · Diamyd Medical AB (1) · Education Development Center, Inc. (1) · Fujian Medical University Union Hospital (1) · Hospital Universitari Joan XXIII de Tarragona. (1) · Mazandaran University of Medical Sciences (1) · Sinocelltech Ltd. (1) · Sinovac Biotech Co., Ltd (1) · The First Affiliated Hospital of Soochow University (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Miami (1) · University of North Carolina, Chapel Hill (1)
China (3) · Belgium (2) · Sweden (2) · United States (2) · Austria (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Iran (1) · Israel (1) · Kenya (1) · Malawi (1) · Netherlands (1)
Athena Sharifi-Razvi (1) · Benjamin Chi, MD, MSc (1) · Fengcai Zhu (1) · Gert Van Assche, MD PhD (1) · Guillermo Prado, PhD (1) · Jiang Wu (1) · Lynda Stranix-Chibanda, MBChB, MMed (1) · Monireh Ghazaeian (1) · Nelly R. Mugo, MBChB (1) · Peter Anderson, PharmD (1) · Yong Yang, MD (1)
PMID 16753240, PMID 19281330, PMID 21142263, PMID 25050644, PMID 25926532, PMID 26472037, PMID 27080532, PMID 28207330, PMID 29041861, PMID 30514652, PMID 35835755, PMID 36162740, PMID 37383290, PMID 40037214, PMID 8888088
R01AA014515 (1), R01AI157859 (1)